<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="19907">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01780311</url>
  </required_header>
  <id_info>
    <org_study_id>Arezzo008</org_study_id>
    <nct_id>NCT01780311</nct_id>
  </id_info>
  <brief_title>Catheter Ablation Versus Antiarrhythmic Drugs for Outflow Tract Ventricular ARrhythmias</brief_title>
  <acronym>AVATAR</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedale San Donato</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, parallel, open study comparing catheter ablation versus antiarrhythmic drugs
      for outflow tract ventricular arrhythmias
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>SF-36 score</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of life improvement according to SF-36 score variations</description>
  </primary_outcome>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Premature Complexes</condition>
  <arm_group>
    <arm_group_label>Antiarrhythmic drugs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Flecainide or Propafenone or Sotalol (oral, standard dosage)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABLATION</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter Ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)</intervention_name>
    <arm_group_label>Antiarrhythmic drugs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter Ablation</intervention_name>
    <arm_group_label>ABLATION</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. presence of ventricular ectopic beats (VEB) with left-bundle-branch block morphology or
        right-bundle-branch block morphology and positive concordance throughout the chest leads,
        inferior axis and at least one of the following:

          1. &gt;2000 isolated VEB/24h

          2. symptomatic monomorphic ventricular tachycardia

          3. left ventricular disfunction supposed to be due to tachycardia-induced cardiomyopathy

        Exclusion Criteria:

          1. known structural heart disease

          2. pregnancy

          3. life expectancy &lt; 1 year
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cardiovascular Department, Ospedale S.Donato</name>
      <address>
        <city>Arezzo</city>
        <state>AR</state>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pasquale Notarstefano, MD</last_name>
      <email>notarstefano2001@yahoo.it</email>
    </contact>
    <investigator>
      <last_name>Leonardo Bolognese, MD, FESC</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pasquale Notarstefano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simone Grotti</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 30, 2013</lastchanged_date>
  <firstreceived_date>January 25, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ospedale San Donato</investigator_affiliation>
    <investigator_full_name>Leonardo Bolognese, MD</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Propafenone</mesh_term>
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
